Evidence map›Paper›PMID 26518748›Full record

Trial reportHaematologica2016

Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.

Kieron Dunleavy, Stefania Pittaluga, Margaret Shovlin, Mark Roschewski, Catherine Lai, Seth M Steinberg, Elaine S Jaffe, Wyndham H Wilson

Registry-linked trialAbstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03586999 (Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03586999 phase1 / phase2completednot on this mapstarted 2018, after this paper: background citation

Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma

TypeinterventionalSponsorUniversity of Colorado, DenverRan2018 to 2022Enrolled18ConditionsPeripheral T Cell LymphomaArmsNivolumab, Etoposide, Prednisolone, Oncovin, Cyclophosphamide
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. T-cell lymphomas, a challenging disease: types, treatments, and future.International journal of clinical oncology · 2017
    Review
  10. Review
  11. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum.Hematology. American Society of Hematology. Education Program · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kieron DunleavyLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA dunleavk@mail.nih.gov.
Stefania PittalugaLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Margaret ShovlinLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Mark RoschewskiBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Catherine LaiLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Seth M SteinbergBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Elaine S JaffeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Wyndham H WilsonLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Funding

Lymphoma Disease Discovery and DefintionZIASC000550 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$16.9M
Intramural NIH HHS
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Large-Cell, AnaplasticMaleMiddle AgedPrednisoneSurvival RateVincristineCyclophosphamideDoxorubicinEtoposidePrednisoneVincristinedose-adjustedEPOCHphase IIsystemic aplastic large cell lymphoma

Identifiers

PMID26518748
PMCPMC4697904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.